Similar articles

• Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series.

  Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L. Valiyil R, et al. Arthritis Care Res (Hoboken). 2010 Sep;62(9):1328-34. doi: 10.1002/acr.20219. Arthritis Care Res (Hoboken). 2010. PMID: 20506493 Free PMC article.
• [Anti-signal recognition particle autoantibody positive myopathy].

  Bodoki L, Vincze M, Hortobágyi T, Griger Z, Csonka T, Dankó K. Bodoki L, et al. Ideggyogy Sz. 2014 Sep 30;67(9-10):347-53. Ideggyogy Sz. 2014. PMID: 25518264 Review. Hungarian.
• Immune-mediated necrotising myopathy associated with antibodies to the signal recognition particle treated with a combination of rituximab and cyclophosphamide.

  Fernandes das Neves M, Caetano J, Oliveira S, Delgado Alves J. Fernandes das Neves M, et al. BMJ Case Rep. 2015 Aug 3;2015:bcr2014206250. doi: 10.1136/bcr-2014-206250. BMJ Case Rep. 2015. PMID: 26240092 Free PMC article.
• Inflammatory myopathy with anti-SRP antibodies: case series of a South Australian cohort.

  Basnayake SK, Blumbergs P, Tan JA, Roberts-Thompson PJ, Limaye V. Basnayake SK, et al. Clin Rheumatol. 2015 Mar;34(3):603-8. doi: 10.1007/s10067-014-2512-7. Epub 2014 Feb 5. Clin Rheumatol. 2015. PMID: 24497174
• Juvenile dermatomyositis: immunopathogenesis, role of myositis-specific autoantibodies, and review of rituximab use.

  Chiu YE, Co DO. Chiu YE, et al. Pediatr Dermatol. 2011 Jul-Aug;28(4):357-67. doi: 10.1111/j.1525-1470.2011.01501.x. Pediatr Dermatol. 2011. PMID: 21793879 Review.